GSK's vaccine sales, including RSV and Shingrix, decline amid changing US recommendations, impacting Q3 performance and ...

Shares of GlaxoSmithKline (GSK) Pharmaceuticals surged up to 3.4 per cent at Rs 2719.90 per share on the BSE in Wednesday’s ...

GlaxoSmithKline said its key brands held their market share and continued to stay in line with the respective category performance. GlaxoSmithKline Pharmaceuticals on October 29 reported a 16 percent ...

GlaxoSmithKline Pharmaceuticals Limited reported that its revenue from operations in the second quarter of FY25 crossed Rs 1000 crore, up 5 per cent Year-on-Year. Profit After Tax (PAT) for the ...

GlaxoSmithKline Pharmaceuticals reported a notable 16% rise in consolidated net profit for the September quarter, reaching Rs 252 crore. This growth was driven by robust sales and brand performance.

GlaxoSmithKline Pharmaceuticals on Tuesday reported a 16 per cent year-on-year increase in its consolidated net profit to Rs ...

GlaxoSmithKline Pharmaceuticals reports a 16% jump in Q2 net profit to Rs 252 crore, driven by strong sales across segments.

In March 2023, my 94-year-old mother had a shingles episode on the right side of her neck, head, ear and (to a lesser degree) right cheek. The active ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation unjustified, leading to a "Strong Buy" rating. The company’s diversified ...

The site is slated to help produce freeze-dried vaccines such as the company's respiratory syncytial virus launch Arexvy and its shingles vaccine Shingrix. GSK pumps £200M+ into UK manufacturing ...